Format

Send to

Choose Destination
Dermatology. 2014;228(2):136-44. doi: 10.1159/000351557. Epub 2014 Feb 15.

Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.

Author information

1
Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Abstract

BACKGROUND:

Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking.

OBJECTIVE:

The aims of the present study were to evaluate the efficacy of propranolol for the treatment of IH, to identify favorable prognostic factors in propranolol-treated IH, and to evaluate the safety of propranolol for the treatment of IH.

METHODS:

Clinical data were recorded from the electronic files and digital photographs of 99 patients with IH attending a tertiary pediatric medical center (2008-2011). Findings were evaluated by regression in volume and color changes.

RESULTS:

The male-to-female ratio was 1:4. Age at treatment initiation was 9.4 ± 10.1 months; 15% of the treated hemangiomas were beyond the proliferative phase (17-54 months). The propranolol starting dose was 2 mg/kg/day. Duration of the treatment was 8.5 ± 3.2 months. All but 1 patient responded to treatment. A longer treatment course was required for segmental and deep hemangiomas. Mild side effects occurred in 32% of patients. Recurrence occurred in 13% of patients.

CONCLUSION:

Lesions located on the face are better responders when treatment is started early. Treatment should continue up to age 12-15 months, with a longer course for segmental or deep hemangiomas.

PMID:
24556822
DOI:
10.1159/000351557
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center